Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy

Alnylam Pharmaceuticals Inc ALNY entered a strategic agreement with Roche Holdings AG RHHBY to develop and commercialize zilebesiran.

Zilebesiran, Alnylam's investigational RNAi therapeutic for the treatment of hypertension, is currently in Phase 2 of development. 

The partnership allows for a bold development plan to disrupt the hypertension treatment paradigm globally while advancing Alnylam's P5x25 strategy.

Roche provides Alnylam with a global footprint and a proven track record of developing and commercializing novel therapies in complex markets. 

Also Read: Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars.

Hypertension affects more than 1.2 billion patients globally.

Under the terms of the agreement, Alnylam will receive an upfront cash payment of $310 million and is eligible to receive additional substantial near-term payments, including development milestone payments over the next few years, as well as regulatory and sales milestones, for a potential deal value of up to $2.8 billion. 

In addition, Alnylam is entitled to an equal profit share in the U.S., where Alnylam and Roche will co-commercialize zilebesiran. 

Roche obtained the exclusive right to commercialize zilebesiran outside the U.S. in exchange for low double-digit royalties on net sales of zilebesiran outside of the U.S.

Additionally, Alnylam will lead a joint clinical development plan for the first indication with Roche's participation, which includes a cardiovascular outcomes trial before submission of zilebesiran for regulatory approval, with all development costs shared 40% by Alnylam and 60% by Roche. 

Roche may lead development for additional indications in the future.

Price Action: ALNY shares are up 0.06% at $200.20 during the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!